x

Search for a clinical trial

* (*) mandatory field

96 Result(s)

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member =

National clinical trial(s)

BELGIUM

VLAAMS BRABANT
LEUVEN

A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
University Hospitals Leuven - Gasthuisberg
Reference Centre for NeuroMuscular Diseases - UZLeuven

BELGIUM

VLAAMS BRABANT
LEUVEN

A Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy.
University Hospitals Leuven - Gasthuisberg
Reference Centre for NeuroMuscular Diseases - UZLeuven

BELGIUM

VLAAMS BRABANT
LEUVEN

CANADA

Ontario
LONDON

FRANCE

AUVERGNE-RHONE-ALPES
NOT YET IDENTIFIED - FR

FRANCE

ILE-DE-FRANCE
PARIS

GERMANY

Baden-Württemberg
FREIBURG

MD-NET Project R17: Immunosuppressive therapy of the Duchenne Muscular Dystrophy with low dosis Prednisone and Cyclosporin A (Phase III) - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen

GERMANY

Baden-Württemberg
FREIBURG

GERMANY

Baden-Württemberg
FREIBURG

GERMANY

Baden-Württemberg
FREIBURG

Ongoing trial
FOR-DMD: Double-blind randomized phase III trial to find optimum steroid regimen for Duchenne Muscular Dystrophy - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen

GERMANY

Baden-Württemberg
FREIBURG

Ongoing trial
Funded by an IRDiRC memberAn Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy (Phase III) - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen

GERMANY

Baden-Württemberg
FREIBURG

GERMANY

Baden-Württemberg
FREIBURG

Funded by an IRDiRC memberA Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy - DE - Completed
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen

GERMANY

Baden-Württemberg
FREIBURG

Recruiting trial
Ongoing trial
Funded by an IRDiRC memberA Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Neuropädiatrie und Muskelerkrankungen

GERMANY

Nordrhein-Westfalen
ESSEN

ITALY

CAMPANIA
NAPOLI

Ongoing trial
(FOR-DMD): Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
AOU Seconda Università degli Studi di Napoli - Centro storico
Servizio di Cardiomiologia e Genetica Medica

ITALY

LAZIO
ROMA

A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
IRCCS Ospedale Pediatrico Bambino Gesù
Unità di Malattie Neuromuscolari e Neurodegenerative - Laboratorio di Medicina Molecolare

ITALY

LAZIO
ROMA

Ongoing trial
A Phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy - IT
IRCCS Ospedale Pediatrico Bambino Gesù
Unità di Malattie Neuromuscolari e Neurodegenerative - Laboratorio di Medicina Molecolare

ITALY

LAZIO
ROMA

Funded by an IRDiRC memberAn Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy (Phase III) - IT
IRCCS Ospedale Pediatrico Bambino Gesù
Unità di Malattie Neuromuscolari e Neurodegenerative - Laboratorio di Medicina Molecolare

ITALY

LOMBARDIA
MILANO

ITALY

VENETO
PADOVA

Ongoing trial
(FOR-DMD): Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Azienda Ospedaliera Universitaria di Padova - Campus Biomedico Pietro d'Abano
Neuromuscular Laboratory

SPAIN

Cataluña
ESPLUGUES DE LLOBREGAT

SPAIN

Cataluña
ESPLUGUES DE LLOBREGAT

SPAIN

Cataluña
ESPLUGUES DE LLOBREGAT

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Comunidad Valenciana
VALENCIA

Ongoing trial
Funded by an IRDiRC memberA Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología

SWEDEN

Stockholms läns landsting
STOCKHOLM

UNITED KINGDOM

Greater London
LONDON

UNITED KINGDOM

Greater London
LONDON

UNITED KINGDOM

Greater London
LONDON

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED STATES

Florida
GAINESVILLE

Multinational clinical trial(s)

UNITED KINGDOM

Greater London
LONDON

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

Ongoing trial
Funded by an IRDiRC memberSCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
Newcastle upon Tyne Hospitals NHS Trust
Institute of Genetic Medicine